Shares of infrastructure construction company Primoris (NYSE:PRIM) fell 3.1% in the afternoon session after Guggenheim downgraded the stock to Neutral from a Buy rating. The analyst noted that the ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...